Open AccessRenoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
Author(s) -
Tomohiko Yamamoto,
Shinichiro Miura,
Kohji Shirai,
Hidenori Urata
Publication year - 2019
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr3671
Subject(s) - tolvaptan , medicine , diuretic , acute decompensated heart failure , loop diuretic , heart failure , cardiology , intensive care medicine
While reduction of accumulated body fluid using loop diuretics is a commonly used therapeutic option for acute heart failure (AHF), some patients, especially those with chronic kidney disease (CKD), show significantly poor treatment response to loop diuretics. Tolvaptan (TLV) has shown effectiveness against AHF in several studies. We have been using TLV for AHF treatment, and it displayed favorable outcome even in patients with CKD. This study aimed to assess the therapeutic effectiveness of TLV in AHF patients.